Literature DB >> 18539245

Outcome of sarcoidosis.

Sonoko Nagai1, Tomohiro Handa, Yutaka Ito, Kousuke Ohta, Manabu Tamaya, Takateru Izumi.   

Abstract

Sarcoidosis is a chronic granulomatous inflammatory disease of unknown etiology with heterogeneous outcome. Based on the natural history or clinical treatment course, the outcomes of cases can be divided into two wings: spontaneous regression (self-limited disease) or progression of extensive fibrotic lesions as a postgranulomatous fibrosis. In addition to examining these outcomes, this article focuses on several related concepts, including chronicity (persistence of the lesions), relapse/recurrence, deterioration, and mortality. It also reviews the outcomes from the point of view of relevant clinical phenotypes, the natural disease course, the effects of treatment, and the effects of lung transplantation. Finally, it considers the effects of pulmonary hypertension, various genetic factors on the outcomes, and the efficacy of several novel therapeutic drugs in treating sarcoidosis.

Entities:  

Mesh:

Year:  2008        PMID: 18539245     DOI: 10.1016/j.ccm.2008.03.006

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  17 in total

1.  Effect of smoking and gender on pulmonary function and clinical features in sarcoidosis.

Authors:  Willane Krell; Julie M Bourbonnais; Rajat Kapoor; Lobelia Samavati
Journal:  Lung       Date:  2012-07-08       Impact factor: 2.584

2.  Outcome of pulmonary sarcoidosis: a population-based study 1976-2013.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Eva M Carmona; Eric L Matteson
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

3.  Early prediction of sarcoidosis prognosis with HLA typing: a 5 year follow-up study.

Authors:  Ezgi Ozyilmaz; Ozlem Goruroglu Ozturk; Ali Durmaz; Orhan Othman Hasan; Bugra Guzelbaba; Gulsah Seydaoglu; Sedat Kuleci; Ismail Hanta; Eren Erken; Ali Kocabas
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

4.  Sarcoidosis in Israel: Clinical Outcome Status, Organ Involvement, and Long-Term Follow-Up.

Authors:  Natalia Markevitz; Gali Epstein Shochet; Yair Levi; Lilach Israeli-Shani; David Shitrit
Journal:  Lung       Date:  2017-05-15       Impact factor: 2.584

Review 5.  Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?

Authors:  Lindsay J Celada; Wonder P Drake
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

6.  Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease.

Authors:  Karen C Patterson; Beverly S Franek; Joachim Müller-Quernheim; Anne I Sperling; Nadera J Sweiss; Timothy B Niewold
Journal:  Cytokine       Date:  2013-02-04       Impact factor: 3.861

7.  ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.

Authors:  Andriy O Samokhin; Frank Bühling; Franz Theissig; Dieter Brömme
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

8.  Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis.

Authors:  Kyra A Oswald-Richter; Bradley W Richmond; Nicole A Braun; Joan Isom; Susamma Abraham; Thyneice R Taylor; John M Drake; Daniel A Culver; David S Wilkes; Wonder P Drake
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

9.  Increased Risk of Multimorbidity in Patients With Sarcoidosis: A Population-Based Cohort Study 1976 to 2013.

Authors:  Patompong Ungprasert; Eric L Matteson; Cynthia S Crowson
Journal:  Mayo Clin Proc       Date:  2017-11-03       Impact factor: 7.616

10.  HRCT findings of pulmonary sarcoidosis; relation to pulmonary function tests.

Authors:  Fatih Ors; Seyfettin Gumus; Mehmet Aydogan; Sebahattin Sari; Samet Verim; Omer Deniz
Journal:  Multidiscip Respir Med       Date:  2013-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.